Paladin Labs buys miltefosine from AEterna Zentaris; transferred to Knight
AEterna Zentaris (treatments for endocrinology and oncology) has sold Canadian spec pharma Paladin Labs all rights related to miltefosine for $9.2mm (Cdn$9.1mm) in cash.
- Specialty Pharmaceuticals
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.